Dimerix

Dimerix EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Dimerix (DXB.AX) as of Oct 18, 2026 is 64.66. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 182.54 — a change of -64.58% (lower).

EV/Revenue

64.66

YoY

-64.58%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Dimerix is 2026 64.66 . EV/Revenue (Enterprise Value to Revenue) of Dimerix was 2025 182.54 . It decreases by -64.58% lower compared to the previous year.

The Dimerix EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2019
203.68 AUD
Jan 1, 2020
124.08 AUD
Jan 1, 2021
66.90 AUD
Jan 1, 2022
44.51 AUD
Jan 1, 2023
8,023.55 AUD
Jan 1, 2024
471.66 AUD
Jan 1, 2025
182.54 AUD
Jan 1, 2026
64.66 AUD
The Dimerix EV/Revenue history
YEAREV/RevenueYoY
64.66-64.58%
182.54-61.30%
471.66-94.12%
8,023.55+17,928.18%
44.51-33.48%
66.90-46.08%
124.08-39.08%
203.68-40.82%
344.16-35.29%
531.81+9.95%
483.68-60.87%
1,236.13+45.67%
848.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

EV/Revenue (Enterprise Value to Revenue) of Dimerix is 64.66 in 2026.

EV/Revenue (Enterprise Value to Revenue) of Dimerix changed from 182.54 to 64.66, representing a -64.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Dimerix since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Dimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Dimerix

All Key Metrics — Dimerix